Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TuHURA Biosciences ( (HURA) ) has shared an announcement.
On April 2, 2026, TuHURA Biosciences’ board compensation committee approved 2025 performance bonuses and 5% cost-of-living salary increases for President and CEO Dr. James Bianco and CFO Dan Dearborn, underscoring the board’s continued support for the senior leadership team. The new compensation levels follow a year marked by the completion, on June 30, 2025, of TuHURA’s acquisition of Kineta, Inc., which brought in the KVA12123 antibody, renamed TBS-2025, and left TuHURA stockholders holding about 92.4% of the combined company.
The company also released unaudited pro forma condensed combined financial information for the year ended December 31, 2025, presenting how results might have looked had the Kineta merger closed on January 1, 2025. By confirming TuHURA as the accounting acquirer and detailing fair-value recognition of Kineta’s assets, liabilities, and in-process R&D, management is providing stakeholders greater visibility into the financial impact of the business combination and the planned advancement of Kineta’s clinical trials alongside TuHURA’s ongoing studies.
The most recent analyst rating on (HURA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Neutral.
The score is driven primarily by weak financial performance (no revenue, widening losses, and deteriorating cash flow), indicating elevated funding risk. Technicals are relatively neutral with modest positive momentum signals but no strong uptrend. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Nevada-based biopharmaceutical company focused on advancing clinical-stage drug candidates, including antibody therapies, through its own development programs and, following its acquisition of Kineta, Inc., integrating additional immuno-oncology assets such as the novel antibody now designated TBS-2025. The company’s operations and financial reporting center on consolidating these programs under TuHURA’s management and capital structure.
Average Trading Volume: 1,735,518
Technical Sentiment Signal: Sell
Current Market Cap: $93.78M
Learn more about HURA stock on TipRanks’ Stock Analysis page.